Malt

Chromosomal Translocations Involved in Non-Hodgkin Lymphomas
Francisco Vega, MD, PhD; L. Jeffrey Medeiros, MD
Context.The discovery that recurrent chromosomal translocations are involved in the pathogenesis of nonHodgkin lymphomas has greatly improved our understanding of these diseases and revolutionized their diagnosis. Objective.To review the mechanisms by which chromosomal translocations occur and contribute to the pathogenesis of various types of non-Hodgkin lymphomas and to review the utility of molecular genetic methods for the assessment of these translocations. Data Sources and Study Selection.Primary research studies and reviews published in the English language that focus on chromosomal translocation and non-Hodgkin lymphomas. Data Extraction and Synthesis.Chromosomal translocations, which usually result in oncogene activation, occur in many types of B- and T-cell lymphoma, and their detection is helpful for establishing an accurate diagnosis and
monitoring disease following therapy. However, the precise mechanisms that explain how translocations occur remain unknown, although for some types of translocations a clear relationship has been established with immunoglobulin gene rearrangement mechanisms. In recent years, a number of genes deregulated by chromosomal translocations have been identied, and the detailed molecular mechanisms by which chromosomal translocations contribute to the pathogenesis of non-Hodgkin lymphoma are beginning to be elucidated. Conclusions.Molecular genetic analysis has played a major role in improving our understanding of B- and T-cell non-Hodgkin lymphomas and has allowed more precise definition of lymphoma types. Molecular genetic tests to detect these translocations are important ancillary tools for the diagnosis and classication of malignant lymphomas. (Arch Pathol Lab Med. 2003;127:11481160) result of aberrant V(D)J recombinase activity, because cryptic heptamer/nonamer consensus sequences are present in the immediate vicinity of the translocation breakpoints.1,2 The antigen receptor loci of B cells may be subjected to 4 types of modication: recombination of the variable (V), diversity (D), and joining (J) regions, somatic hypermutation of the V segments, immunoglobulin heavy-chain (IgH) gene class switching, and receptor editing. Occasional failures in the control of these processes appear to play an important role in the generation of chromosomal translocations in B-cell lymphomas. These events occur mainly at 2 stages of B-cell development: during V region recombination in B-cell precursors in the bone marrow and during B-cell differentiation in the germinal center microenvironment. Chromosome translocations in T-cell lymphomas also may arise from analogous errors of T-cell receptor (TCR) gene V(D)J recombination.2 However, somatic hypermutation of V segments is rare, and class switching of the TCR genes does not occur in T cells. V(D)J Recombination The development of B cells in the bone marrow is initiated by a site-specic recombination reaction, V(D)J recombination, of the IgH and Ig light-chain genes ( and ).3 For formation of the V region exon of the IgH chain, V, D, and J gene segments are joined, whereas the V region exons of and light chains are composed only of V and J segments.3,4 As shown for IgH in Figure 1, rst a DH segment is joined with a JH segment. This joining is folChromosomal Translocations in LymphomasVega & Medeiros
hromosomal translocations in non-Hodgkin lymphomas can be subdivided into 2 general types. In the rst type, an intact oncogene (or intact coding region) is juxtaposed via the translocation with another gene, usually an antigen receptor gene. As a result, the oncogene becomes transcriptionally deregulated. Historically, this was the rst type of translocation discovered in nonHodgkin lymphomas. Examples of this type include the t(8;14) in Burkitt lymphoma/leukemia and the t(14;18) in follicular lymphoma. In the second type of translocation, 2 genes (usually nonantigen receptor genes) are disrupted, and portions of each gene are juxtaposed, resulting in a fusion gene, chimeric mRNA, and a novel protein. This type of chromosomal translocation occurs in some types of non-Hodgkin lymphoma, such as the t(2;5) in anaplastic large cell lymphoma (ALCL), but is best known in acute and chronic myeloid leukemias.
MECHANISMS OF CHROMOSOMAL TRANSLOCATIONS Overall, the precise molecular mechanisms underlying chromosomal translocation remain largely unknown, and different mechanisms have been proposed to explain recurrent translocations in various lymphoma types. In some cases, the evidence suggests that translocation is a
Accepted for publication February 19, 2003. From the Division of Pathology and Laboratory Medicine, University of Texas M. D. Anderson Cancer Center, Houston. Reprints: L. Jeffrey Medeiros, MD, Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, Box 72, 1515 Holcombe Blvd, Houston, TX 77030 (e-mail: jmedeiro@mdanderson.org). 1148 Arch Pathol Lab MedVol 127, September 2003
Figure 1. IgH gene rearrangement. The IgH chain gene in its germline conguration has approximately 120 variable (V) regions, up to 30 diversity (D) regions, 6 joining (J) regions, and 9 constant (C) regions. Each of these regions are discontinuous. Three gene segments (V, D, and J) are joined to create a heavy-chain V region gene. This process occurs in 2 steps: DH joins to JH and then VH joins to DH JH. Figure 2. Coding end processing. A, The endonuclease activity of the RAG protein complexes makes 2 single-strand DNA breaks at sites just 5 of each recognition signal sequence (RSS), and a DNA hairpin is created. B, The DNA hairpin is nicked open by a single-strand break, also by the RAG proteins. The nicking can happen at various points along the hairpin, which leads to sequence variability in the eventual joint. When nicks occur on only one strand, the resulting protruding strand ends with palindromic nucleotides coming from the opposite strand. C, These nucleotide additions are termed P nucleotides and are a characteristic of variable, diversity, joining (VDJ) recombination because they are the direct result of DNA hairpin resolution. D, Once coding ends are opened up, more modications can take place. Nucleotides may be removed by exonuclease activity, and nongermline nucleotides (N sequences) may be added by the terminal deoxynucleotidyl transferase (TdT), further increasing the diversity of V region genes. E and F, Pairing of strands, exonuclease cleavage, DNA synthesis, and ligation occur to form the coding joint. The sum of those modications of the coding ends before religation (P and N addition and nucleotide deletion) is referred to as coding end processing and constitutes the hallmark of the VDJ recombination process. Figure 3. The npm-alk fusion protein resulting from the t(2;5)(p23;q35). The major breakpoint region to the right of the transmembrane domain is indicated by a vertical arrow. OD indicates oligomerization domain; MB, metal-binding domain; AD, acidic amino acid clusters; NLS, nuclear localization signals; LBS, putative ligand binding site for pleiotropin; TM, transmembrane domain; TK, tyrosine kinase catalytic domain. Figure 4. The t(8;14) breakpoints in sporadic and endemic Burkitt lymphoma (BL). In sporadic BL, the breakpoints occur near the c-myc gene and in the switch (S) region of IgH (yellow arrows). Exon 1, including the major promoters of c-myc, is deleted; however, the coding regions (exons 2 and 3) remain structurally intact. The coding regions are indicated in white, and the noncoding regions are gray. In endemic BL, the breakpoints are located more than 100 kb 5 of the rst exon of c-myc and in the joining (J) region of IgH (blue arrows). The chromosome 8 breakpoints of the variant translocations (arrowhead) occur 3 to the gene. Restriction fragment length (Southern blot) analysis can be used to detect c-myc gene rearrangements in sporadic BL but not in endemic BL. The reverse is true for detecting IgH rearrangements using genomic J region probes.
lowed by a VH to DHJH joining, which can be either in frame (correct for encoding antibody sequences) or out of frame. When in-frame VDJ joining is achieved, and the precursor cell is now a B cell that can proceed with maturation by undergoing Ig light-chain gene rearrangements.
Arch Pathol Lab MedVol 127, September 2003
Following out-of-frame VDJ joining, a second attempt at VDJ joining occurs on the other allele. Recombination involves the introduction of doublestrand breaks in DNA by the products of the recombination-activating genes, RAG-1 and RAG-2.5 These breaks
Chromosomal Translocations in LymphomasVega & Medeiros 1149
occur at specic recognition signal sequences (RSSs) adjacent to the V, D, and J elements (3 to the V regions, 5 and 3 to the D regions, and 5 to the J regions). An RSS is composed of conserved heptamer and nonamer motifs separated by a relatively nonconserved spacer region of either 12 or 13 base pairs (bp), and efcient recombination requires one RSS of each type. Several other proteins are needed in this process, including DNA ligase IV; DNAdependent protein kinase; Ku, which is a heterodimer (Ku 70:Ku 80) that associates tightly with DNA-dependent protein kinase; and the DNA-repair protein, x-ray repair complementing defective in Chinese hamster 4 (XRCC4).6 The characteristic steps in the V(D)J recombination process are illustrated in Figure 2. Defects during V(D)J recombination, during the phases in which physiological breaks are generated or in which they are joined, can result in chromosomal translocations.7,8 At least 2 distinct mechanisms involving V(D)J recombination can lead to translocation. First, an illegitimate V(D)J recombination may occur between a legitimate Ig or TCR locus and an illegitimate proto-oncogene locus bearing a functional RSS. Translocations that involve antigen receptor gene loci in precursor T-cell lymphoblastic lymphoma/leukemia, such as the t(10;14)(q24;q11) involving the TCR/ locus, seem to be mediated by such a mechanism.9,10 In a second mechanism, only the Ig or TCR locus breaks are mediated by V(D)J recombination. Breaks at the locus bearing the proto-oncogene are initiated by other mechanisms of cleavage. The t(11;14)(q13;q32) in mantle cell lymphoma appears to be an example of this second mechanism.9,11 Several models have been proposed to explain the occurrence of chromosomal breaks in proto-oncogene loci. Translocations may occur through elements such as crossover hotspot instigator (chi)-like sequences, which promote recombination. In agreement with this hypothesis, chi-like sequences are found within the 2 predominant breakpoint regions of the bcl-2 locus of the t(14;18) and the major translocation cluster of the bcl-1 locus of the t(11; 14).12 Another possible mechanism has been attributed to the transpositional activity of the RAG proteins.7,8 Somatic Hypermutation Somatic hypermutation is a process by which mutations, mainly single-nucleotide exchanges or small insertions or deletions of DNA, are introduced at a high rate into the V segments of normal germinal center B cells after exposure to antigen.13 These mutations require double-stranded DNA breaks prior to the mutational event and thus increase the likelihood that translocations may occur.13 Others have suggested that translocations involving the cmyc gene in endemic Burkitt lymphoma (BL) probably arise as by-products of somatic hypermutation.13 In addition, some translocations of the bcl-6 gene in diffuse large B-cell lymphomas (DLBCL) and of the IgG FcIIb receptor in follicular lymphoma show translocation breakpoints in somatically mutated V region genes.14,15
dem repeats located upstream of each constant-region gene (with the exception of C). The switch results in a change in the effector functions of the antibody but leaves the V(D)J region unaltered. For several types of B-cell lymphoma, chromosomal translocations into IgH chain S regions have been described, such as translocations involving c-myc in sporadic BL,16 bcl-3 [t(14;19)] in B-cell chronic lymphocytic leukemia (CLL),17 bcl-6 [t(3;14)] in DLBCL,18 muc1 [t(1;14)] in large cell lymphoma,19 and fgfr3 [t(4;14)], c-maf [t(14;16)], and mum/irf4 [t(t6;14)] in plasma cell myeloma (PCM).2022 Receptor Editing Receptor editing is a process by which one of the expressed antibody polypeptide light chains, or , is replaced by the other. The process of Ig light-chain loci receptor editing is mediated by secondary rearrangements of the V region gene, usually involving upstream V segments and downstream J segments. This process also involves DNA-strand breaks and may play a role in the generation of chromosomal translocations in B-cell lymphomas. MECHANISMS OF ONCOGENE FUSION The molecular mechanisms by which 2 genes are disrupted resulting in the formation of a novel hybrid gene remain largely unknown. In the cases of the t(11;18) and t(2;5), breakpoints in the api2 and alk genes, respectively, are clustered, suggesting that structural features make these breakpoints sites (introns) more vulnerable to rearrangement. Different molecular mechanisms can be implicated, such as homologous recombination mediated by Alu elements,23 TRANSLIN activity,24 cleavage at purine/ pyrimidine repeat regions,25 topoisomerase II subunit exchange,26 and repair of DNA breaks with nonhomologous chromosomes.27 In the t(11;18), Baens and colleagues28 found AluSx repeat sequences within or close to the breakpoint region in intron 7 of api2. However, no AluSx sequences were consistently observed close to the breakpoint sites in malt1 on chromosome 18. Thus, homologous recombination between Alu elements as a mechanism for generating the t(11;18) seems unlikely. Sato and colleagues29 found a V(D)J heptamer consensus sequence close to the breakpoint in intron 7 of api2 and several heptamer-like sequences in the malt1 gene. However, no nonamer-like sequences were found in either the api2 or malt1 genes. One cannot exclude the possibility that the clustering of breakpoints delineates the portions of the proteins required in the fusion for its oncogenic properties. With this explanation, one must hypothesize that illegitimate random recombinations can occur during the normal cell division process. Random cleavage of the genes can be followed by attempts to repair the breaks and joining of the loci, and those clones containing the fusion transcript survive and have a growth advantage. Thus, the breakpoints appear to be clustered. However, in the case of t(11;18) and t(2;5), this explanation seems unlikely.29,30 COMMON TRANSLOCATIONS IN NON-HODGKIN LYMPHOMAS ALCL of T- or Null-Cell Lineage ALCL accounts for approximately 3% of adult and 10% to 30% of childhood lymphomas and includes a subset of tumors that carry the t(2;5)(p23;q35).31 This translocation
Chromosomal Translocations in LymphomasVega & Medeiros
IgH Switching IgH switching is a process by which B cells normally replace the IgM and IgD constant regions with IgG, IgA, or IgE. This process is mediated by a recombination event that occurs in germinal center B cells after antigen exposure and results in deletion of DNA between involved switch (S) regions. These S regions are arrays of short tan1150 Arch Pathol Lab MedVol 127, September 2003
Table 1. Chromosomal Translocations in Anaplastic Large Cell Lymphoma

Translocation Involved Genes*
t(2;5)(p23;q35) alk and npm t(1;2)(q25;p23) tpm3 and alk t(2;3)(p23;q21) alk and tfg inv(2)(p23q35) alk and atic t(X;2)(q11-12;p23) msn and alk t(2;17)(p23;q23) alk and cltcl * alk indicates anaplastic lymphoma kinase; npm, nucleophosmin; tpm3, tropomyosin 3; tfg, TRK-fused gene; atic, 5-aminoimidazole-4carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; msn, moesin; and cltcl, clathrin heavy chainlike.
has been identied in 40% to 70% of ALCLs of the T-cell and null-cell types, most commonly in tumors that occur in younger patients. Structure of the Translocation. The t(2;5) fuses the nucleophosmin (NPM) gene, npm, at 5q35 with the anaplastic lymphoma kinase (ALK) gene, alk, at 2p23. The fusion gene encodes a 80-kd chimeric protein, of which 117 NH2terminal residues of NPM are linked to the intracytoplasmic portion of ALK (C-terminal residues 10581620) (Figure 3).30,32 The reciprocal alknpm fusion gene is not transcribed at signicant levels and thus probably does not contribute to the pathogenesis of ALCL.32 Other rare translocations involving the alk locus at 2p23 that also result in alk overexpression have been characterized (Table 1). All except one of the variant fusions cloned thus far have had the same breakpoint within the alk gene, in a 1935-bp intron located between the exons encoding the transmembrane and juxtamembrane domains of alk, suggesting that this chromosomal region is very susceptible to breakage. The exception is the alk breakpoint in the moesin (msn)alk translocation, which is localized in an exonic sequence 17 bp downstream of the 5 end of the rst alk exon. Pathophysiology. The fusion of npm with alk encodes a constitutively activated tyrosine kinase that is a potent oncogene.33 The causative role of this fusion protein in lymphomagenesis was conrmed by the development of lymphomas in mice transplanted with bone marrow cells transduced with human NPMALK fusion protein.34 Motifs within NPM regulate dimerization of NPMALK, inducing conformational changes in the ALK component, resulting in a constitutive activation of the kinase domain.33 In all the variant 2p23 abnormalities, the NPM protein is replaced by another protein that contains some form of oligomerization motif, suggesting that the mechanism underlying ALK activation is similar in all and that the signal transduction pathways activated are probably identical. Although the pathogenesis of ALCL is unknown, recent in vitro studies have provided evidence that several mechanisms, including ras, signal transducer and activator of transcription (STAT), phospholipase C , and phosphatidylinositol 3 kinase pathways, may be involved in deregulation of cell proliferation and apoptosis in ALCLs.35 Rassidakis and colleagues36 have shown that ALK-positive ALCLs have low levels of the antiapoptotic protein Bcl-2 and a higher apoptotic rate than ALK-negative ALCLs. Thus, differential expression of Bcl-2 family proteins may play a role in the good response to chemotherapy observed in patients with ALK-positive ALCLs. ALK-positive ALCLs appear to be clinically homogeArch Pathol Lab MedVol 127, September 2003
neous, regardless of their morphology or whether they have the t(2;5) or other translocations involving alk. Based on the expression of ALK, several investigators have proposed restricting the denition of ALCL to include only ALK-positive tumors, leaving ALK-negative cases in a separate category, most likely anaplastic variants of peripheral T-cell lymphoma. Methods of Detection. In most pathology laboratories, ALK immunostaining, given its ease, rapidity, specicity, and low cost, is the most useful screening technique for detecting abnormalities involving the alk locus.35 ALK is normally expressed in nerve cells but is not expressed in normal hematopoietic tissues. However, as a result of translocations or other abnormalities involving alk, ALK is overexpressed. Thus, immunostaining with antibodies specic for the cytoplasmic portion of ALK provides indirect evidence for abnormalities involving the alk gene, most often the t(2;5). ALK expression can be detected immunohistochemically with the monoclonal antibody ALK1 or with polyclonal antibodies (eg, p80, ALK-11). Malignant cells carrying the t(2;5) have both a cytoplasmic and nuclear pattern of staining with anti-ALK antibodies because of dimerization of NPMALK with wild-type NPM. The latter has nuclear localization motifs.37 In some studies, 15% to 20% of ALK-positive ALCLs show only cytoplasmic expression of ALK, suggesting the presence of a variant translocation not involving npm. The lack of tight clustering within the involved npm and alk introns precludes analysis using standard polymerase chain reaction (PCR) methods, but reverse transcription (RT) or long-range PCR methods can be used.38 These methods can detect the t(2;5) but not other variant translocations involving alk. RT-PCR requires RNA and generates amplicons of identical size, making it difcult to exclude contamination if it occurs. Long-range PCR has the advantages that gene transcription is not required and amplicons of distinct size for each case are generated. However, high-quality DNA is necessary for this approach. Conventional cytogenetic analysis provides the most complete information because these methods allow detection of the t(2;5) and all variant translocations involving alk. However, viable cells that can be induced to divide are required, which is a major drawback. Fluorescence in situ hybridization (FISH) methods can be used to detect either the t(2;5) or alk rearrangements, the latter representing either t(2;5) or variant translocations involving alk. Restriction fragment length analysis using genomic probes derived from either alk or npm also can be used to detect gene rearrangements. However, this approach is labor intensive and is seldom used routinely. Burkitt Lymphoma/Leukemia Burkitt lymphoma/leukemia is a highly aggressive Bcell neoplasm characterized by chromosomal translocations involving the c-myc gene.39 These translocations occur in virtually all cases. The t(8;14) is most common, found in approximately 80% to 85% of cases. The t(2;8) and t(8;22), also known as the variant translocations, occur in approximately 10% to 15% of tumors. Structure of the Translocation. The t(8;14) juxtaposes the c-myc gene, normally at 8q24, 5 to the IgH locus on the derivative chromosome 14. In the t(2;8) and t(8;22), the Ig and Ig light-chain loci are juxtaposed 3 to the c-myc gene on the derivative chromosome 8. The breakpoints on chromosome 8 are variable and widely scattered (Figure
4). For example, in endemic (African) BL, the breakpoints are usually located far 5 (100 kilobases [kb]) to the cmyc gene. In contrast, in sporadic BL the chromosome 8 breakpoints occur immediately 5 to or within the c-myc gene. Similarly, the breakpoints on chromosome 14 are variable. In endemic BL, most breakpoints occur within the J region of IgH. In sporadic BL, the breakpoints occur more commonly within the S or constant (C) regions, upstream of C, C, or C (Figure 4).40 Pathophysiology. As a result of the t(8;14) or variant translocations, Myc protein is overexpressed. Myc inuences multiple cellular processes, including cell proliferation, differentiation, apoptosis, and metabolism, that contribute positively or negatively to cell transformation. The c-myc gene is one of the immediate early growth response genes that are rapidly induced in quiescent cells upon mitogenic induction, playing an important role in mediating the transition from quiescence to proliferation. Myc induces expression of cyclins D1 and D2, allowing these molecules to form complexes with cyclin-dependent kinase inhibitors. These cyclin Dcyclin-dependent kinase complexes sequester the cell cycle inhibitors p27 and p21, thereby releasing the cell cycle from inhibition.41 The c-myc gene is also able to stimulate apoptosis (programmed cell death), and abrogation of Myc-induced apoptosis is probably necessary to allow its proliferation effect. Concomitant activation of bcl-2 or alterations in the p19(arf)-mdm2-p53 pathway can nullify the apoptotic inuence of c-myc.42 These cooperative effects have been observed in cell culture. When normal cells are placed in medium with low concentrations of growth factors, such as platelet-derived growth factor, they are arrested in the G0 or G1 stages of the cell cycle but remain viable. Recombinant cells that overexpress c-myc also arrest their growth under these conditions but soon undergo apoptosis. Apparently, the cell senses an inappropriate growth signal from Myc and, in the absence of other growth signals from surface receptors, commits suicide. However, overexpression of bcl-2 rescues c-mycoverexpressing cells from death. Thus, a cell with abundant Myc and Bcl-2 proteins can proliferate in the absence of normal growth factors. Methods of Detection. The c-myc gene potently drives cell division, and metaphases are easily detectable in cell cultures. As a result, the t(8;14) or variant translocations are usually detected by conventional cytogenetic methods. However, viable cells are required. FISH methods are advantageous because cell division and thus viable cells are not required, and the large size of c-myc probes allows detection of virtually all 8q24 breakpoints, as a result of the t(8;14), t(2;8), and t(8;22).43 If c-myc and Ig gene probes are used, the specic translocation can be identied. The number of partner chromosomes and the great variability in breakpoints makes PCR assays impractical. A large number of primer pairs would be needed, and even then all translocations cannot be detected. Restriction fragment length can be used to assess c-myc gene rearrangements in sporadic BL. However, in endemic BL the c-myc breakpoints extend beyond the length of DNA fragments that can be detected using genomic c-myc probes (Figure 4).40 In sporadic BL, a similar approach using J region probes to assess the IgH gene often do not detect rearrangements because the breakpoints occur in the S or C regions. In contrast, IgH gene rearrangements
1152 Arch Pathol Lab MedVol 127, September 2003
can be detected in endemic BL because the breakpoints occur in the J region (Figure 4). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) represents approximately 6% to 7% of non-Hodgkin lymphomas in the United States. A number of molecular abnormalities have been detected in CLL/ SLL, but their roles in pathogenesis have yet to be elucidated. Using conventional cytogenetic analysis, chromosomal abnormalities have been identied in 50% to 60% of CLL/ SLL cases, including trisomy 12, abnormalities of 13q14, deletions of 11q, and abnormalities of 14q32. FISH analysis reveals that approximately 80% of the cases have abnormal karyotypes.44,45 Deletion 13q14 is the most common abnormality in CLL/SLL, occurring in up to 50% of cases. Trisomy 12 is found in 10% to 20% of cases, and 11q deletions occur in 20% of CLL/SLL cases.46 Chromosomal translocations occur in only a small subset of CLL/SLL cases. In approximately 5% of cases, the bcl-2 gene at 18q21 is involved in either the t(2;18)(p12; q21) or t(18;22)(q21;q11), involving the Ig (chromosome 2p12) or Ig (chromosome 22q11) gene loci.46 In these translocations, the chromosome 18 breakpoints occur 5 to the rst exon of bcl-2. Other chromosomal translocations identied uncommonly in CLL/SLL include the t(14;19) and the t(2;14). The t(14;19)(q32,q13) is a rare cytogenetic abnormality that is found in less than 5% of cases of CLL/SLL and is associated with young age at time of initial diagnosis, atypical cytologic features, and poor prognosis.47 The t(14; 19) juxtaposes the bcl-3 gene at 19q13 with IgH in a headto-head conguration, resulting in overexpression of bcl3. Restriction fragment length analysis, using genomic bcl3 probes, is the standard method for detection of bcl-3 gene rearrangements.47 The t(2;14)(p13;q32) is a rarely described abnormality identied in uncommon tumors that has been designated as childhood CLL. The translocation breakpoints for 2 such cases have been cloned.48 The t(2;14) juxtaposes the bcl-11A gene at 2p13 with IgH at 14q32. The bcl-11A gene is the human homologue of mouse evi-9, which is deregulated in murine myeloid leukemias after proviral integration. The t(2;14) may be associated with the Ig-unmutated subset of CLL/SLL.49 Diffuse Large B-Cell Lymphoma DLBCL is a molecularly heterogeneous group of B-cell lymphomas in which conventional cytogenetic analysis has shown a wide variety of molecular abnormalities (Table 2). Two of the more common translocations include those involving bcl-6 and the t(14;18). The t(14;18) is present in 2030% of DLBCL cases. These tumors are thought to be of follicle center origin and may represent transformation of follicular lymphoma (FL) presenting as de novo DLBCL. Other chromosomal translocations identied in DLBCL include the t(14;15)(q32;q1113), t(1;22)(q22;q11), t(1;14)(q21;q32), and t(10;14)(q24;q32) and involve the genes bcl-8, fcgrIIb, muc-1, and nf-b2, respectively. Approximately 4% of DLBCL carry the t(14;15) or bcl-8 gene rearrangements; the other translocations are less frequent. These translocations do not result in fusion proteins but rather in the juxtaposition of oncogenes with Ig gene loci.
Table 2. Chromosomal Translocations in Diffuse Large B-Cell Lymphoma

Translocation Involved Genes
t(14;18)(q32;q21) t(3;4)(q27;p13) t(3;6)(p27;p21.3) t(3;6)(p27;p21.2) t(3;7)(p27;p12) t(3;11)(p27;q23.1) t(3;3)(p27;q29) t(3;13)(q27;q14) t(3;16)(p27;p11) t(3;12)(p27;12q23-24.1) t(3;18)(p27;p11.2) t(3;14)(p27;q32) t(3;6)(p27;p12) t(3;16)(p27;p13) t(3;14)(p27;q32) t(3;2)(p27;p12) t(3;22)(p27;q11) t(14;15)(q32;q11-13) t(1;22)(q22;q11) t(1;14)(q21;q32) t(10;14)(q24;q32) t(1;13)(p32;q14) t(1;7)(q21;q22) der(6)t(6;8)(q11;q11) t(5;16)(?;q11-q12) t(19;22)(q13;q11-q13)
IgH and bcl-2 bcl-6 and rhoh/ttf bcl-6 and H4 histone bcl-6 and pim-1 bcl-6 and ikaros bcl-6 and bob/obf1 bcl-6 and tfrr bcl-6 and 1-plastin bcl-6 and Il-21r bcl-6 and -nac bcl-6 and eif4AII bcl-6 and hsp89 bcl-6 and hsp90 bcl-6 and cIIta bcl-6 and IgH bcl-6 and Ig bcl-6 and Ig IgH and bcl-8 fcgrIIb and Ig muc-1 and IgH nf-b2 and IgH
Recently, Nanjangud and collaborators50 used spectral karyotyping to identify new recurrent chromosomal translocations in DLBCL, including the t(1;13)(p32;q14), t(1; 7)(q21;q22), and der(6)t(6;8)(q11;q11) and potentially the t(5;16)(?;q11-q12) and t(19;22)(q13;q11-q13). The genes at these loci are not currently known. Structure and Pathophysiology of bcl-6. Rearrangements of the bcl-6 gene are found in 30% to 40% of DLBCL cases, approximately 20% of acquired immunodeciency syndromeassociated DLBCL, and 5% to 14% of FL cases.51 The bcl-6 gene resides at the 3q27 locus, spans 26 kb, and has 10 exons that encode the Bcl-6 protein consisting of 706 amino acids.52,53 This gene is highly promiscuous and is translocated with a number of partner chromosome loci (Table 2). The IgH gene locus is most commonly involved, in 40% to 50% of cases. The bcl-6 breakpoints are concentrated in a 4-kb region of 3q27 that includes the promoter and the rst noncoding exon. In most cases, the breakpoints are located immediately 3 to the rst exon, and as a result bcl-6 exons 210 (spanning the entire coding domain) are juxtaposed to a partner chromosome downstream from heterologous promoters (Figure 5). The bcl-6 gene encodes a zinc-nger transcription factor implicated in germinal center B-cell differentiation, antibody-afnity maturation, and T helper cellmediated responses.53 Translocations involving bcl-6 do not involve its coding regions and thus result in overexpression of structurally intact Bcl-6 protein. The Bcl-6 protein is normally expressed by germinal center B cells, is required for normal germinal center formation, and is downregulated in postgerminal center stages of B-cell maturation. Downregulation of bcl-6 during plasma cell differentiation allows expression of B lymphocyteinduced maturation protein 1, a major regulator of plasma cell differentiation. B lymphocyteinduced maturation protein 1 represses tranArch Pathol Lab MedVol 127, September 2003
scription of c-myc, and in B cells that are poised to differentiate to plasma cells, this drop in c-myc expression is an integral part of terminal differentiation.54 Loss of normal control mechanisms regulating bcl-6 expression is thought to contribute to malignant transformation in germinal centerderived B cells. Point mutations of the regulatory portion of the bcl-6 gene have been detected frequently in germinal center and postgerminal center lymphomas, including FL, DLBCL, and BL, and their signicance in lymphomagenesis is not clear. One study has suggested that the prognostic impact of bcl-6 translocations might depend on whether the gene is juxtaposed with Ig loci or other genes; the cases with nonIg partner chromosomes have a poorer outcome.55 In another study, high levels of bcl-6 gene expression were correlated with a favorable prognosis in patients with DLBCL.56 In one study, DLBCL cases with nonIg/bcl-6 translocations had higher levels of bcl-6 mRNA than cases with Ig/bcl-6 translocations.57 Methods of Detection. Restriction fragment length analysis is used most often because bcl-6 breakpoints are relatively clustered, usually in the rst intron or immediately 5 to the rst exon, and thus bcl-6 gene rearrangements can be readily assessed with a bcl-6 probe.52 FISH probes specic for bcl-6 should produce results comparable to those obtained with restriction fragment length analysis and are less labor intensive.58 The telomeric location of 3q27 makes translocations involving this locus difcult to recognize by conventional cytogenetic techniques. The large number of partner chromosomes precludes routine PCR analysis in the clinical laboratory. Follicular Lymphoma Follicular lymphoma is a neoplasm of follicle center B cells and is characterized by the t(14;18)(q32;q21), detected by conventional cytogenetic techniques in approximately 80% to 90% of cases.59 In the remaining 10% to 20% of FL cases, the t(14;18) is not detectable using any available method. This observation suggests the existence of other mechanisms that dysregulate bcl-2 expression. The t(14;18) is also found in 20% to 30% of DLBCL cases. These tumors are presumably of follicle center cell origin.60 Structure of the Translocation. In the t(14;18), the bcl2 gene on 18q21 is juxtaposed with the IgH gene on 14q32, resulting in overexpression of structurally intact and functional Bcl-2 protein. The breakpoints on chromosome 14 are tightly clustered, occurring immediately 5 to the IgH joining regions. The majority of breakpoints on chromosome 18 also tightly clustered. Two well-known clusters, the major breakpoint cluster region (MBR) and the minor breakpoint cluster region (MCR) (Figure 6),61 are involved in 50% to 60% and 10% to 15% of the cases of FL, respectively. Recently, Albinger-Hegyi and collaborators62 sequenced an approximately 25-kb region of chromosome 18 between the MBR and MCR and detected a third breakpoint cluster region, which they designated the intermediate cluster region.62 Other small breakpoint cluster regions have been reported, including a region 5 to the rst exon of bcl-2 (also involved in 5% of cases of CLL/SLL). Pathophysiology. The t(14;18) has been identied in a signicant proportion of healthy persons.63 In the absence of FL (by all measurable parameters), the signicance of this nding is uncertain but may suggest that the translocation is an early initiating event, with subsequent cumulative oncogenic alterations necessary for manifestation
Figure 5. The (3;14)(q27;q32) translocation. Most of the breakpoints are located in the rst intron or immediately 5 to the rst exon of the bcl6 gene and cause the juxtaposition of bcl-6 exons 210, corresponding to the entire coding domain, downstream from the promoter derived from chromosome 14. The breakpoints in chromosome 14 occur within the switch (S) region of IgH. Thus, the functional consequence of this translocation is the deregulation of bcl-6 expression by promoter substitution. Figure 6. Germline conguration of chromosome 18q21 region involved in t(14;18)(q32;q21). Most of the breakpoints occur in the major breakpoint region (MBR) with a smaller subset in the minor breakpoint cluster region (MCR) (yellow arrowheads). The black, green, orange, and white rectangles represent the range of detection using polymerase chain reaction, Southern blot (SB), uorescent in situ hybridization, and conventional cytogenetic methods, respectively. Figure 7. Germline conguration of chromosome 11q13 region involved in t(11;14)(q13;q32). The ccnd-1 gene is indicated as a green box. The major translocation cluster region accounts for 30% to 40% of all translocations. Minor breakpoint clusters are indicated as mTC1 and mTC2. The black, green, orange, and white rectangles represent the range of detection using polymerase chain reaction, Southern blot (SB), uorescent in situ hybridization, and conventional cytogenetic methods, respectively. Figure 8. The api2 and malt1 genes involved in t(11;18)(q21;q21). All breakpoints occur between exons 7 and 8 of the api2 gene (arrowhead), 3 to the 3 baculovirus inhibitor of apoptosis repeat domain (BIR) motifs. Large arrows indicate the position of the different malt1 breakpoints; small arrows indicate the alternative splice sites used when a breakpoint upstream of 814 base pairs occurs. CARD indicates caspase recruitment domain. The RING nger motif is a distinct zinc-chelating domain involved in mediating proteinDNA and proteinprotein interactions.
of FL. Lower incidence rates of FL have been reported in most Asian countries. However, available published data suggest that the incidence of the t(14;18) in healthy persons in the absence of FL is similar in Western and Asian populations.63,64 The exact mechanisms by which Bcl-2 and related family members regulate apoptosis are not clear, and results of some studies have indicated that bcl-2 expression alone is not sufcient to explain its antiapoptotic activity, as can be observed in cell culture experiments. Low-grade FL cells carrying the t(14;18) undergo apoptosis when cul1154 Arch Pathol Lab MedVol 127, September 2003
tured in vitro, meaning that FL cells are not capable of self-maintenance and lack proper humoral and/or cellular factors that allow their survival. Therefore, other factors or regulatory mechanisms must be involved in FL cell survival. Independent of its antiapoptotic function, Bcl-2 and other Bcl-2 family members can also promote cell-cycle arrest, retarding entry into the cell cycle and accelerating withdrawal from the cell cycle.65,66 Thus, Bcl-2 appears to have a physiological role in inuencing the transition between quiescent and cycling states. Both the antiapoptotic and
the cell-cycle arrest functions of Bcl-2 may explain the indolent nature of FL. Inhibition of apoptosis and cell-cycle arrest may lead to an accumulation of malignant cells over time, without increasing the proliferation rate of the affected cells. Methods of Detection. The tight physical clustering of the MBR and MCR breakpoints facilitates effective screening for the presence of the t(14;18) translocation by standard PCR assays, which are commonly used as tests of choice, particularly in the assessment of minimal residual disease. Using 2 sets of primers specic for the MBR and MCR, PCR can be used to detect the t(14;18) in approximately 60% to 75% of cases.67 This method is also advantageous because assays for MBR and MCR can be applied to archival parafn-embedded tissue. Several investigators have demonstrated the utility and reliability of using real-time PCR methods to detect t(14;18) and to quantify tumor burden in FL patient samples.68,69 However, standard or real-time PCR assays will not detect a subset of cases that can be detected using other methods. At our hospital, the prognosis is thought to be poorer in patients with FL in which the t(14;18) is not detected by the standard PCR approach assessing MBR and MCR.70 A higher detection rate for the t(14;18) may be obtained by analysis of the intermediate cluster region, which also can be assessed by standard PCR methods.62 Detection rates higher than those obtained by standard PCR can be achieved by using long-range PCR, which can detect additional breakpoints.62 However, this technique requires high-quality DNA and has not yet been implemented as a routine detection method in most laboratories. FISH methods using bcl-2 and IgH probes also have been used to detect the t(14;18). These methods have the potential to detect virtually all cases with the t(14;18).71 Restriction fragment length analysis can be used to detect PCR positive cases as well as a subset of cases of FL in which the breakpoints do not occur in the MBR and MCR (Figure 6). Disadvantages of restriction fragment length analysis include the need for chromosome 14 and 18 probes to prove the presence of t(14;18) and the time-consuming and laborious nature of this method. Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is a clinically aggressive B-cell lymphoma that represents approximately 6% of all non-Hodgkin lymphomas in the United States. An almost constant feature in this neoplasm is the presence of the t(11;14)(q13;q32).72 Structure of the Translocation. The t(11;14) juxtaposes the ccnd-1 gene (also known as bcl-1, prad1, and cyclin D1) at 11q13 with an enhancer of the IgH gene at 14q32. Nearly half of these translocations cluster within an 80- to 100bp region known as the major translocation cluster region on chromosome 11q13 (Figure 7).73,74 However, the remainder of chromosome 11 breakpoints are widely scattered over approximately 120 kb. The breakpoints on chromosome 14 occur 5 to 1 of 6 joining regions of IgH. Pathophysiology. As a result of the t(11;14), the ccnd1 gene is overexpressed.72 Overexpression of cyclin D1 protein in the G1 phase of the cell cycle causes early phosphorylation of retinoblastoma protein and acceleration through G1.75,76 Although cyclin D1 overexpression is sufcient to confer transformed properties on broblasts, it is insufcient to transform primary cells or to induce lymphomagenesis in E-cyclin D1 transgenic mice.77 However,
concurrent overexpression of cyclin D1 and either the nmyc or l-myc oncogenes in transgenic mice results in lymphoma formation.78 Thus, other cellular factors in addition to ccnd-1 overexpression appear to play a role in MCL. Various proteins, including the E2F5 transcription factor, its dimerization partner dp2, the cdc28 protein kinase 1, and the products of the cell cycle genes ckd4, mdm2, c-myc, cdc8, and skp2 have been reported to be overexpressed in MCL.79 In addition, several pathways associated with apoptosis are altered and substantially downregulated in MCL. Methods of Detection. FISH methods using probes for chromosomes 11 and 14 are very sensitive and can detect the t(11;14) in up to 95% of MCLs.80,81 Conventional cytogenetic analysis can detect the t(11;14) in at least 70% to 80% of cases (Figure 7). Slow growth, sampling error, or other technical limitations may explain the negative results in 20% to 30% of tumors. Translocations involving the major translocation cluster are amenable to routine PCR analysis, and thus 30% to 40% of MCL cases are positive using these methods.82 However, the large subset of negative cases makes this approach problematic for routine diagnosis. Restriction fragment length analysis, using at least 4 genomic chromosome 11 probes, can detect rearrangements of the bcl-1 locus in approximately 65% to 75% of MCLs.73,74 However, this approach is time consuming and labor intensive, and chromosome 14 probes are also required to prove the presence of the t(11;14). An alternative approach to obtain support for the diagnosis of MCL is to assess the expression of cyclin D1, because all t(11;14) translocations theoretically result in overexpression of cyclin D1. Because normal lymphocytes express very low levels of cyclin D1, not detectable by immunohistochemical methods, these methods are convenient and specic for distinguishing MCL from other types of non-Hodgkin lymphoma. However, a negative immunoreaction does not exclude the diagnosis of MCL because the immunohistochemical approach is relatively insensitive and some MCLs have relatively low levels of cyclin D1.72 Detection of cyclin D1 mRNA by quantitative RT-PCR, in contrast, is very sensitive and distinguishes low levels of cyclin D1 derived from nonoverexpressing lymphomas or normal cells from high levels of cyclin D1 mRNA characteristic of MCL.83 Marginal Zone B-Cell Lymphoma of Extranodal Mucosa-Associated Lymphoid Tissue Type Both types of chromosomal translocations (described earlier) have been implicated in the pathogenesis of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT).84 In the t(11;18)(q21; q21), the api2 gene on 11q21, and the malt1 gene on chromosome 18q21 are disrupted and recombine to form a novel api2malt1 fusion gene on the derivative chromosome 11. In contrast, in the other translocations reported in MALT lymphoma, listed in Table 3, the entire coding region of a gene (malt1, bcl-10) is juxtaposed with an antigen receptor gene. t(11;18)(q21;q21). The t(11;18) is the most frequent chromosomal translocation known to occur in MALT lymphoma, identied in at least one third of cases. The t(11; 18)-positive lymphomas have been reported to involve most extranodal MALT sites, most commonly the gastrointestinal tract and lung. The t(11;18) appears to be specic for MALT lymphomas and has not been identied in
other lymphoma types, including nodal and splenic marginal zone B-cell lymphomas.8587 Structure of the Translocation. The api2 gene is a member of the inhibitor of apoptosis protein family and contains 3 baculovirus inhibitor of apoptosis protein repeat (BIR) domains, a caspase recruitment domain (CARD), and a RING nger domain (Figure 8). The common domain of the inhibitor of apoptosis protein family is the BIR motif, which plays an essential role in inhibiting apoptosis. All breakpoints in the api2 gene occur between exons 7 and 8, 3 to the 3 BIR motifs. Thus, the BIR motif is considered essential to the function of api2malt1. The malt1 gene is a novel gene that has homology with the Ig-like domain of CD22, the laminin-5 3b subunit, and F22D3.6 of Caenorhabditis elegans.87 The C-terminal part of malt1 harbors 2 Ig-like C2 domains and an Ig VDJ4-like sequence. Four different breakpoints occur throughout the malt1 gene, all of which result in the 3 end of the gene being fused in frame with api2 (Figure 8). Pathophysiology. It is hypothesized that fusion of api2 to the C-terminal region of malt1 leads to an increased inhibition of apoptosis, inhibiting the biological activity of caspases 3, 7, and 9 and thereby conferring a survival advantage. The function of the malt1 gene is largely unknown. The api2malt1 protein recently has been shown to activate nf-b, a transcription factor for several survivalrelated genes.88 Recent studies suggest that response of gastric MALT lymphoma to antibiotic therapy can be predicted by the presence or absence of the t(11;18).89,90 Lymphomas that carry the t(11;18) are unlikely to respond to antibiotic therapy. By contrast, those lymphomas negative for the t(11; 18) are more often associated with immunologic stimulation mediated by Helicobacter pylori and are more likely to respond to antibiotic therapy. To date, the t(11;18) only rarely has been detected in high-grade B-cell lymphomas arising in MALT sites. Thus, t(11;18)-positive low-grade MALT lymphomas seem to have a low likelihood of transforming to large B-cell lymphoma. Because low-grade MALT lymphomas are commonly associated with a highgrade component and both components have been shown to be clonally related in some patients,91,92 there may be 2 types of low-grade MALT lymphoma: one not associated with the t(11;18) that may transform to high-grade lymphoma and the other that carries the t(11;18) and rarely transforms to high-grade lymphoma. Alternatively, the translocation may be not present in all tumor cells, implicating the presence of subclones with or without the translocation, the latter likely to transform to a high-grade lymphoma. Although the possibility that the t(11;18) is lost from the clone during tumor progression cannot be excluded, this possibility seems unlikely because most other types of low-grade B-cell lymphoma that undergo highgrade transformation retain their initial molecular abnormalities while acquiring additional genetic alterations. Methods of Detection. Cytogenetic analysis of MALT lymphomas is hampered by low yield and poor quality of metaphase spreads. These problems are related in part to small size of biopsy specimens, the slow growth of these tumors, and bacterial contamination of biopsy specimens from some extranodal sites, such as the gastrointestinal tract. RT-PCR methods used to detect the t(11;18) have great sensitivity and may be applied for evaluation of minimal residual disease. A number of different transcripts of various sizes have been detected using these methods.
Table 3. Chromosomal Translocations in Marginal Zone B-Cell Lymphoma of Extranodal MucosaAssociated Lymphoid Tissue (MALT) Type
t(11;18)(q21;q21) t(14;18)(q32;q21) t(1;14)(p22;q32) t(1;2)(p22;p12) * api indicates apoptosis inhibitor.
api2 and malt1 malt1 and IgH bcl-10 and IgH bcl-10 and Ig
Baens et al93 also developed a reliable real-time RT-PCR assay to detect the t(11;18), based on the 53 exonuclease activity of Taq polymerase. A major disadvantage of this approach is the need for fresh-frozen tissue specimens to allow extraction of RNA. Interphase FISH assays using api2- and malt1-specic probes can be applied to fresh and archival tissues or nuclei.86 FISH is easy to interpret, nearly as sensitive as RT-PCR, and highly specic and may detect translocations of malt1 involving partner genes other than api2 as well as translocations of api2 involving partner genes other than malt1. t(14;18)(q32;q21). The t(14;18)(q32;q21) has been recently identied in approximately 20% of MALT lymphomas.94 In this translocation, the malt1 gene is juxtaposed with the IgH gene at 14q32, resulting in malt1 overexpression. To date, the t(14;18) in MALT lymphomas has been identied by conventional cytogenetics and FISH methods. The t(11;18) and t(14;18) appear to be mutually exclusive in MALT lymphomas.94 t(1;14)(p22;q32). The t(1;14)(p22;q32) has been identied rarely in MALT lymphomas.95 As a result of the t(1; 14), the entire bcl-10 gene, at chromosome 1p22, is juxtaposed with the IgH gene, resulting in Bcl-10 overexpression.96 Another rare chromosomal translocation involving bcl-10 also has been identied recently in MALT lymphoma, the t(1;2)(q22;p12).97 In this translocation, the bcl-10 gene is juxtaposed with the Ig gene on 2p12 (Table 3). Structure of the Translocation. The bcl-10 gene has 4 exons within an 11.7-kb segment of the genome. The gene encodes a protein of 233 amino acids, with residues 13 101 forming a CARD similar to that of api2, whereas 132 amino acids at the C-terminus of the protein contain no known motifs.96 Pathophysiology. The bcl-10 and IgH genes on the derivative chromosome 14 are oriented in a head-to-head fashion. As a result, bcl-10 comes under the control of the IgH gene enhancers resulting in overexpression of Bcl-10.96 Wild-type bcl-10 encodes a protein containing an NH2-terminal CARD that weakly promotes apoptosis, activates nfb, and behaves as a tumor suppressor gene in in vitro assays.96,98 The t(1;14) truncates the bcl-10 gene at its Cterminus, 3 to the CARD motif. Truncated Bcl-10 protein loses its proapoptotic function but retains its ability to activate nf-b. Mutations of bcl-10 also occur infrequently, in about 5% of MALT lymphomas.99 Recently, Maes et al100 reported that bcl-10 genomic mutations do not play an important role in the pathogenesis or the progression of gastric MALT lymphomas. Methods of Detection. Because the t(1;14) is rare, its presence is not assessed routinely with molecular diagnostic methods. Conventional cytogenetic analysis is the main method of detection. Expression of Bcl-10 protein can be detected by immunohistochemistry, and in a study using these methods Bcl-10 was found in the cytoplasm
Table 4. Chromosomal Translocations in Plasma Cell Myeloma

t(4;14)(p16;q32) t(14;16)(q32;q23) t(16;22)(q23;q11) t(11;14)(q13;q32) t(6;14)(p25;q32)
fgfr3, mmset, and IgH IgH and c-maf c-maf and Ig ccnd-1 and IgH mum/irf4 and IgH
of normal B cells, including marginal zone B cells.101 By contrast, Bcl-10 is predominantly expressed in the nuclei of MALT lymphoma cells with t(1;14). Moreover, up to 50% of MALT lymphomas without this translocation also express Bcl-10, predominantly in the nucleus, at a moderate level, and many of these cases carry the t(11;18). Thus, aberrant nuclear Bcl-10 expression observed in a subset of MALT lymphomas seems to be associated with the presence of either the t(11;18) or the t(1;14).99 Nuclear expression of Bcl-10 is found in a higher proportion of gastric MALT lymphomas with dissemination to lymph nodes or distant sites than in low-stage tumors.102 Plasma Cell Myeloma Early studies of plasma cell myeloma (PCM) revealed that structural and numeric abnormalities are common in metaphases analyzed using conventional cytogenetic methods (Table 4). However, cytogenetic analysis was only informative in approximately 40% of cases because of the limited mitotic activity of myeloma cells. In contrast, modern cytogenetic methods (conventional and FISH) reveal that most cases of PCM are cytogenetically abnormal. Others have reported that 3 types of cytogenetic abnormalities are associated with an adverse outcome103: the presence of any chromosomal translocation, abnormalities of 11q, and deletions of 13q. The 14q32 translocations involving IgH are the most frequent event in PCM involving a variety of partner chromosome loci, mostly 11q13, 4p16.3, 16q23, and 6p25, where the genes ccnd-1, fgfr3/mmset, c-maf, and mum/irf4 are located, respectively.104 The incidence of 14q32 translocations increases with the stage of disease: 50% in monoclonal gammopathy of uncertain signicance, 60% to 65% in intramedullary PCM, 70% to 80% in extramedullary PCM, and 90% in PCM cell lines. These translocations result in juxtaposition of oncogenes with IgH, and the IgH breakpoints most often involve S regions. The t(11;14)(q13;q32) is one of the most common translocations identied in PCM, in almost 30% of the PCM cases with a cytogenetically detectable 14q.105 This translocation transposes the ccnd-1 gene with an IgH S region, resulting in ccnd-1 overexpression. The chromosome 11 breakpoints are dispersed over a 100- to 330-kb region centromeric (5) to the ccnd-1 gene and do not involve the major translocation cluster, as is common in MCL. Thus, these breakpoints differ substantially from those of the t(11;14) in MCL. A subset of these cases also overexpress a second putative oncogene, myeov (myeloma overexpressed gene), 360 kb centromeric to ccnd-1.106 The t(4;14)(p16;q32) is present in 20% to 30% of cases of PCM.20 Cloning of the t(4;14) has identied 2 genes, fgfr3 (broblastic growth factor receptor 3) on der(14) and mmset (multiple myeloma SET domain), also known as whsc1 (Wolf-Hisrschhorn syndrome candidate gene 1) on
der(4), that are dysregulated as a result of their juxtaposition with Ig gene enhancers.107 As a result of the t(4;14), fgfr3 is constitutively activated. Additional fgfr3 gene mutations may be correlated with tumor progression. Moreover, fgfr3 can play a ras-like role in PCM tumor progression. The mum (multiple myeloma oncogene 1)/irf4 (interferon regulatory factor 4) gene has been identied as a myeloma-associated putative oncogene that is activated at the transcriptional level as a result of t(6;14)(p25;q32) because of its juxtaposition with the IgH enhancer.22 This translocation occurs in approximately 20% of PCM. This mum/ irf4 gene transforms broblasts in culture, suggesting that it may contribute to PCM oncogenesis. Approximately 10% of cases of PCM carry the t(14; 16)(q32;q23).108 The 5 cloned breakpoints on 16q23 occur over a region of 5501350 kb centromeric to c-maf, all but 1 of them within the 800-kb intron of the oxidoreductase gene, wwox/for (fragile site FRA16D oxidoreductase).109,110 This region is a common chromosomal fragile site that undergoes frequent homozygous deletion in adenocarcinomas of stomach, lung, colon, and ovary. The variant t(16;22)(q23;q11), detected in the myeloma cell line 8226, has its breakpoint telomeric to c-maf, not involving wwox/ for.111 The mechanism whereby c-maf might contribute to PCM pathogenesis is unknown. Methods of Detection. FISH methods are the most useful approach for detecting translocations in PCM. The poor growth of plasma cells in culture compromises the ability of conventional cytogenetic analysis to detect various abnormalities. In the t(4;14) and t(6;14), the breakpoints occur in the telomeric region of chromosomes 4 and 6, respectively, and result in karyotypically silent translocations. There is a limited role for restriction fragment length analysis and PCR methods to assess PCM. Precursor Lymphoblastic Lymphoma/Leukemia Most cases of precursor lymphoblastic lymphoma/leukemia in which chromosomal translocations have been identied and cloned have presented as leukemia and are not the subject of this review. Whether these translocations also occur in patients with conditions that present as lymphoma seems likely but is generally not proven. The chromosomal translocations identied are shown in Table 5. t(9;14)(p13;q32) The t(9;14)(p13;q32) translocation was reported in approximately 50% of nodal-based non-Hodgkin lymphoma cases, with plasmacytoid differentiation.112 This nding led others to suggest that the t(9;14) is common in lymphoplasmacytic lymphoma/Waldenstro m macroglobulinemia. However, in our experience cases of lymphoplasmacytic lymphoma/Waldenstro m macroglobulinemia involving bone marrow are rarely positive for t(9;14).113 The t(9;14) also has been observed in a case of splenic marginal zone lymphoma.114 These results suggest that the t(9;14) is more closely linked to nodal or splenic lymphomas with plasmacytoid differentiation, such as nodal or splenic marginal zone B-cell lymphoma, than it is to lymphoplasmacytic lymphoma/Waldenstro m macroglobulinemia. Structure of the Translocation. Molecular characterization of the t(9;14) has shown that the IgH locus is translocated in a head-to-head conguration with the pax-5 (paired homeobox 5) gene on chromosome 9p13.112 As a
Table 5. Chromosomal Translocations in Precursor Lymphoblastic Lymphoma/Leukemia

Disease Translocation Involved Genes*
Precursor B cell
Precursor T cell
t(12;21)(p13;q22) t(9;22)(q34;q11.2) t(1;19)(q23;p13) t(17;19)(q22;p13) t(5;14)(q31;q32) t(v;11)(v;q23) t(1;14)(q25;q32) t(10;14)(q24;q11) t(7;10)(q34;q24) t(11;14)(p13;q11) t(7;11)(q34;p13) t(11;14)(p15;q11) t(8;13)(p11;q11) t(8;14)(q24;q11) t(1;14)(q32;q11) t(1;7)(p34;q34) t(7;9)(q34;q32) t(7;9)(q34;q34) t(1;7)(p32;q34) t(7;19)(q34;q13)
tel and aml1 bcr and abl e2a and pbx1 hlf and e2a il3 and IgH mll and numerous partners lhx4 and IgH hox11 and TCR/ TCR and hox11 lmo2 and TCR/ TCR and lmo2 lmo1 and TCR/ fgfr1 and znf198 c-myc and TCR/ tal1 and TCR/ tal1 and TCR TCR and tal2 TCR and tan1 lck and TCR TCR and ly I1
* TCR indicates T-cell receptor.
result, the potent E enhancer of the IgH gene is brought into close proximity with the pax-5 promoter. Pathophysiology. The pax-5 gene encodes a transcription factor known as B-cellspecic activator protein, which is essential for B-cell proliferation and differentiation.115 B-cellspecic activator protein is universally transcribed during B-cell ontogeny but is downregulated at the plasma cell stage of differentiation, showing a timeexpression pattern similar to the bcl-6 gene.116 Expression of pax-5 is restricted to B cells, the testis in adults, and the brain and liver in the fetus. Loss of the normal control mechanisms regulating pax-5 expression is thought to contribute to malignant transformation in lymphomas carrying the t(9;14) translocation. As a result of this translocation, during the terminal phase of B-cell differentiation, the physiological downregulation of pax-5 transcription does not occur. Hence, overexpression of pax-5 may prevent activated B cells from exiting the cell cycle and could thus block completion of the plasma cell differentiation program. Methods of Detection. Most diagnostic laboratories do not routinely assess for the t(9;14). Thus, this translocation is most frequently detected by conventional cytogentic analysis. A double-color FISH approach, using probes specic for IgH and pax-5, has been reported, and restriction fragment length analysis can also be used.117
References
1. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B-cell lymphomas. Oncogene. 2001;20:55805594. 2. Tycko B, Sklar J. Chromosomal translocations in lymphoid neoplasia: a reappraisal of the recombinase model. Cancer Cells. 1990;2:18. 3. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302: 575581. 4. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381:751758. 5. Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science. 1990;248: 15171523. 6. Fugmann SD, Lee AI, Shockett PE, Villey IJ, Schatz DG. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol. 2000;18:495527. 7. Hiom K, Melek M, Gellert M. DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463470. 8. Agrawal A, Eastman QM, Schatz DG. Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. Nature. 1998; 394:744751.
9. Marculescu R, Le T, Simon P, Jaeger U, Nadel B. V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites. J Exp Med. 2002;195:8598. 10. Raghavan SC, Kirsch IR, Lieber MR. Analysis of the V(D)J recombination efciency at lymphoid chromosomal translocation breakpoints. J Biol Chem. 2001;276:2912629133. 11. Welzel N, Le T, Marculescu R, et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res. 2001;61:16291636. 12. Wyatt RT, Rudders RA, Zelenetz A, DeLellis RA, Krontiris TG. BCL2 oncogene translocation is mediated by a chi-like consensus. J Exp Med. 1992;175: 15751588. 13. Goossens T, Klein U, Kuppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci U S A. 1998;95:24632468. 14. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res. 2000;60:23352341. 15. Callanan MB, Le Baccon P, Mossuz P, et al. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Natl Acad Sci U S A. 2000;97:309314. 16. Magrath I. The pathogenesis of Burkitts lymphoma. Adv Cancer Res. 1990; 55:133270. 17. McKeithan TW, Takimoto GS, Ohno H, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer. 1997;20:6472. 18. Baron BW, Nucifora G, McCabe N, Espinosa R, Le Beau MM, McKeithan TW. Identication of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc Natl Acad Sci U S A. 1993;90:52625266. 19. Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood. 2000;95:29302936. 20. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3; q32.3) in multiple myeloma is associated with increased expression and activating mutations of broblast growth factor receptor 3. Nat Genet. 1997;16:260 264. 21. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:44574463. 22. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17:226230. 23. Jeffs AR, Benjes SM, Smith TL, Sowerby SJ, Morris CM. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. Hum Mol Genet. 1998;7:767776. 24. Aoki K, Suzuki K, Sugano T, et al. A novel gene, Translin, encodes a recombination hotspot binding protein associated with chromosomal translocations. Nat Genet. 1995;10:167174. 25. Boehm T, Mengle-Gaw L, Kees UR, et al. Alternating purine-pyrimidine tracts may promote chromosomal translocations seen in a variety of human lymphoid tumours. EMBO J. 1989;8:26212631. 26. Baguley BC, Ferguson LR. Mutagenic properties of topoisomerase-targeted drugs. Biochim Biophys Acta. 1998;1400:213222. 27. Reichel M, Gillert E, Nilson I, et al. Fine structure of translocation break-
points in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene. 1998;17:30353044. 28. Baens M, Steyls A, Dierlamm J, De Wolf-Peeters C, Marynen P. Structure of the MLT gene and molecular characterization of the genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell lymphomas of MALT type. Genes Chromosomes Cancer. 2000;29:281291. 29. Sato Y, Akiyama Y, Tanizawa T, et al. Molecular characterization of the genomic breakpoint junction in the t(11;18)(q21;q21) translocation of a gastric MALT lymphoma. Biochem Biophys Res Commun. 2001;280:301306. 30. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkins lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14:21752188. 31. Delsol G, Ralfkiaer E, Stein H, Wright D, Jaffe E. Anaplastic large cell lymphoma. In: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon. France: IARC Press; 2001:230235. 32. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkins lymphomaassociated NPManaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997;17:23122325. 33. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 1997;90:29012910. 34. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:56235637. 35. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001;114:741760. 36. Rassidakis GZ, Sarris AH, Herling M, et al. Differential expression of BCL2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol. 2001;159:527535. 37. Mason DY, Pulford KA, Bischof D, et al. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res. 1998;58:10571062. 38. Sarris AH, Luthra R, Cabanillas F, Morris SW, Pugh WC. Genomic DNA amplication and the detection of t(2;5)(p23;q35) in lymphoid neoplasms. Leuk Lymphoma. 1998;29:507514. 39. Hecht JL, Aster JC. Molecular biology of Burkitts lymphoma. J Clin Oncol. 2000;18:37073721. 40. Neri A, Barriga F, Knowles DM, Magrath IT, Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1988;85:27482752. 41. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:53215333. 42. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 1998; 12:29842991. 43. Kluin PH, Schuuring E. FISH and related techniques in the diagnosis of lymphoma. Cancer Surv. 1997;30:320. 44. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999;77:266281. 45. Geisler CH, Philip P, Hansen MM. B-cell chronic lymphocytic leukaemia: clonal chromosome abnormalities and prognosis in 89 cases. Eur J Haematol. 1989;43:397403. 46. Dyer MJS, Oscier DG. The conguration of the immunoglobulin genes in B-cell chronic lymphocytic leukemia. Leukemia. 2002;16:973984. 47. Michaux L, Dierlamm J, Wlodarska I, Bours V, Van den Berghe H, Hagemeijer A. t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet. 1997;94:3643. 48. Richardson AL, Humphries CG, Tucker PW. Molecular cloning and characterization of the t(2;14) translocation associated with childhood chronic lymphocytic leukemia. Oncogene. 1992;7:961970. 49. Kuppers R, Sonoki T, Satterwhite E, et al. Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene. Leukemia. 2002;16:937939. 50. Nanjangud G, Rao PH, Hegde A, et al. Spectral karyotyping identies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood. 2002;99:25542561. 51. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995;14:62096217. 52. Kawamata N, Miki T, Fukuda T, Hirosawa S, Aoki N. The organization of the BCL6 gene. Leukemia. 1994;8:13271330. 53. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inammation. Nat Genet. 1997;16:161 170. 54. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997;276:596599. 55. Akasaka T, Ueda C, Kurata M, et al. Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/ BCL6. Blood. 2000;96:29072909. 56. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945951. 57. Ueda C, Uchiyama T, Ohno H. Immunoglobulin (Ig)/BCL6 versus non-Ig/
BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA. Blood. 2002;99:26242625. 58. Sanchez-Izquierdo D, Siebert R, Harder L, et al. Detection of translocations affecting the BCL6 locus in B cell non-Hodgkins lymphoma by interphase uorescence in situ hybridization. Leukemia. 2001;15:14751484. 59. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med. 1987;316:7984. 60. Jacobson JO, Wilkes BM, Kwaiatkowski DJ, Medeiros LJ, Aisenberg AC, Harris NL. bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer. 1993;72:231236. 61. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:14401443. 62. Albinger-Hegyi A, Hochreutener B, Abdou MT, et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am J Pathol 2002;160:823832. 63. Aster JC, Kobayashi Y, Shiota M, Mori S, Sklar J. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol. 1992;141:291299. 64. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002;99:4265 4275. 65. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A. 1996;93:95459552. 66. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene. 1996;13:15111519. 67. Estalilla OC, Medeiros LJ, Manning JT Jr, Luthra R. 5 3 Exonucleasebased real-time PCR assays for detecting the t(14;18)(q32;21): a survey of 162 malignant lymphomas and reactive specimens. Mod Pathol. 2000;13:661666. 68. Ladetto M, Sametti S, Donovan JW, et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol. 2001;29:183193. 69. Sanchez-Vega B, Vega F, Hai S, Medeiros LJ, Luthra R. Real-time t(14; 18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis: a novel and rapid approach that allows accurate quantitation and size determination of bcl-2/JH fusion sequences. Mod Pathol. 2002;15:448453. 70. Lopez-Guillermo A, Cabanillas F, McDonnell TJ, et al. Correlation of bcl2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93:30813087. 71. Poetsch M, Weber-Matthiesen K, Plendl HJ, Grote W, Schlegelberger B. Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-articial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation. J Clin Oncol. 1996;14:963969. 72. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33: 720. 73. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. Leukemia. 1993;7:241245. 74. Medeiros LJ, Van Krieken JH, Jaffe ES, Raffeld M. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood. 1990;76:20862090. 75. Jiang W, Kahn SM, Zhou P, et al. Overexpression of cyclin D1 in rat broblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993;8:34473457. 76. Lukas J, Jadayel D, Bartkova J, et al. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene. 1994;9:21592167. 77. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:21242130. 78. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:34873495. 79. Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 2001;98: 787794. 80. Remstein ED, Kurtin PJ, Buno I, et al. Diagnostic utility of uorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol. 2000;110:856862. 81. Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, De Mascarel A, Merlio JP. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol. 2002;15:517525. 82. Luthra R, Sarris AH, Hai S, et al. Real-time 53 exonuclease-based PCR assay for detection of the t(11;14)(q13;q32). Am J Clin Pathol. 1999;112:524 530. 83. Medeiros LJ, Hai S, Thomazy VA, Estalilla OC, Romaguera J, Luthra R. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkins lymphomas. Mod Pathol. 2002;15:556564. 84. Vega F, Medeiros LJ. Marginal-zone B-cell lymphoma of extranodal mucosa-associated lymphoid tissue type: molecular genetics provides new insights into pathogenesis. Adv Anat Pathol. 2001;8:313326. 85. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specicity of
API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000;156:11831188. 86. Dierlamm J, Baens M, Stefanova-Ouzounova M, et al. Detection of t(11; 18)(q21;q21) by interphase uorescence in situ hybridization using API2 and MLT specic probes. Blood. 2000;96:22152218. 87. Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosaassociated lymphoid tissue. Oncogene. 1999;18:57855794. 88. Lucas PC, Yonezumi M, Inohara N, et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J Biol Chem. 2001;276:1901219019. 89. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11; 18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:3940. 90. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:12861294. 91. Montalban C, Manzanal A, Castrillo JM, Escribano L, Bellas C. Low grade gastric B-cell MALT lymphoma progressing into high grade lymphoma: clonal identity of the two stages of the tumour, unusual bone involvement and leukemic dissemination. Histopathology. 1995;27:8991. 92. Peng H, Du M, Diss TC, Isaacson PG, Pan L. Genetic evidence for a clonal link between low and high-grade components in gastric MALT B-cell lymphoma. Histopathology. 1997;30:425429. 93. Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol. 2000;156:1433 1439. 94. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:23352339. 95. Wotherspoon AC, Pan LX, Diss TC, Isaacson PG. Cytogenetic study of Bcell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet Cytogenet. 1992;58:3538. 96. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999; 96:3545. 97. Achuthan R, Bell SM, Leek JP, et al. Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma. Genes Chromosomes Cancer. 2000;29:347349. 98. Hofmann K. The modular nature of apoptotic signaling proteins. Cell Mol Life Sci. 1999;55:11131128. 99. Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet. 1999;22:6368. 100. Maes B, Demunter A, Peeters B, De Wolf-Peeters C. BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. Blood. 2002;99:13981404. 101. Ye H, Dogan A, Karran L, et al. BCL10 expression in normal and neo-
plastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am J Pathol. 2000;157:11471154. 102. Liu H, Ye H, Dogan A, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 2001;98:11821187. 103. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:42504256. 104. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:56115622. 105. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic ndings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:4149. 106. Janssen JW, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood. 2000;95:26912698. 107. Chesi M, Brents LA, Ely SA, et al. Activated broblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001;97:729736. 108. Sawyer JR, Lukacs JL, Munshi N, et al. Identication of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 1998;92:42694278. 109. Bednarek AK, Lain KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 2000;60:21402145. 110. Ried K, Finnis M, Hobson L, et al. Common chromosomal fragile site FRA16D sequence: identication of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet. 2000;9:16511663. 111. Chesi M, Kuehl WM, Bergsagel PL. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol. 2000; 11:131135. 112. Oft K, Parsa NZ, Filippa D, Jhanwar SC, Chaganti RS. t(9;14)(p13;q32) Denotes a subset of low-grade non-Hodgkins lymphoma with plasmacytoid differentiation. Blood. 1992;80:25942599. 113. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic ndings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116:543549. 114. Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood. 1998;92:38653878. 115. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci U S A. 1996;93:61296134. 116. Barberis A, Widenhorn K, Vitelli L, Busslinger M. A novel B-cell lineagespecic transcription factor present at early but not late stages of differentiation. Genes Dev. 1990;4:849859. 117. Tamura A, Miura I, Iida S, et al. Interphase detection of immunoglobulin heavy chain gene translocations with specic oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet. 2001;129:19.

Malt

Hochgeladen von

Dokumentinformationen

Originalbeschreibung:

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Malt

Hochgeladen von

Copyright:

Verfügbare Formate

Chromosomal Translocations Involved in Non-Hodgkin Lymphomas

Francisco Vega, MD, PhD; L. Jeffrey Medeiros, MD

Table 1. Chromosomal Translocations in Anaplastic Large Cell Lymphoma

Table 2. Chromosomal Translocations in Diffuse Large B-Cell Lymphoma

t(11;18)(q21;q21) t(14;18)(q32;q21) t(1;14)(p22;q32) t(1;2)(p22;p12) * api indicates apoptosis inhibitor.

Table 4. Chromosomal Translocations in Plasma Cell Myeloma

t(4;14)(p16;q32) t(14;16)(q32;q23) t(16;22)(q23;q11) t(11;14)(q13;q32) t(6;14)(p25;q32)

Table 5. Chromosomal Translocations in Precursor Lymphoblastic Lymphoma/Leukemia

* TCR indicates T-cell receptor.

1158 Arch Pathol Lab MedVol 127, September 2003

Chromosomal Translocations in LymphomasVega & Medeiros

Arch Pathol Lab MedVol 127, September 2003

Chromosomal Translocations in LymphomasVega & Medeiros 1159

1160 Arch Pathol Lab MedVol 127, September 2003

Chromosomal Translocations in LymphomasVega & Medeiros

Das könnte Ihnen auch gefallen